MA53543A - Vaccins peptidiques - Google Patents

Vaccins peptidiques

Info

Publication number
MA53543A
MA53543A MA053543A MA53543A MA53543A MA 53543 A MA53543 A MA 53543A MA 053543 A MA053543 A MA 053543A MA 53543 A MA53543 A MA 53543A MA 53543 A MA53543 A MA 53543A
Authority
MA
Morocco
Prior art keywords
peptide vaccines
vaccines
peptide
Prior art date
Application number
MA053543A
Other languages
English (en)
Inventor
Zsolt Csiszovszk
Julianna Liszewicz
Orsolya Lorincz
Mónika Megyesi
Levente Molnar
Katalin Pantya
Eszter Somogyi
Eniko Toke
József Toth
Original Assignee
Treos Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1814366.9A external-priority patent/GB201814366D0/en
Priority claimed from GBGB1814367.7A external-priority patent/GB201814367D0/en
Priority claimed from GBGB1814364.4A external-priority patent/GB201814364D0/en
Priority claimed from GBGB1814365.1A external-priority patent/GB201814365D0/en
Application filed by Treos Bio Ltd filed Critical Treos Bio Ltd
Publication of MA53543A publication Critical patent/MA53543A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
MA053543A 2018-09-04 2019-09-03 Vaccins peptidiques MA53543A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1814366.9A GB201814366D0 (en) 2018-09-04 2018-09-04 Peptide vaccines
GBGB1814367.7A GB201814367D0 (en) 2018-09-04 2018-09-04 Peptide Vaccines
GBGB1814364.4A GB201814364D0 (en) 2018-09-04 2018-09-04 Peptide vaccines
GBGB1814365.1A GB201814365D0 (en) 2018-09-04 2018-09-04 Peptide vaccines

Publications (1)

Publication Number Publication Date
MA53543A true MA53543A (fr) 2021-07-14

Family

ID=67874441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053543A MA53543A (fr) 2018-09-04 2019-09-03 Vaccins peptidiques

Country Status (16)

Country Link
US (2) US11666644B2 (fr)
EP (1) EP3846845A1 (fr)
JP (2) JP7642530B2 (fr)
KR (1) KR20210086612A (fr)
CN (1) CN113329761A (fr)
AU (1) AU2019334437A1 (fr)
BR (1) BR112021004071A2 (fr)
CA (1) CA3110760A1 (fr)
CL (2) CL2021000532A1 (fr)
CO (1) CO2021004019A2 (fr)
IL (1) IL281224A (fr)
MA (1) MA53543A (fr)
MX (1) MX2021002449A (fr)
SA (1) SA521421371B1 (fr)
SG (1) SG11202101888YA (fr)
WO (1) WO2020048990A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018226566B2 (en) 2017-03-03 2025-01-23 Treos Bio Limited Population-based immunogenic peptide identification platform
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3990006A1 (fr) * 2019-06-28 2022-05-04 The Francis Crick Institute Limited Nouveaux antigènes anticancéreux et procédés
WO2022009052A2 (fr) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
KR102846817B1 (ko) * 2023-06-28 2025-08-18 주식회사 이온셀 Ct83 항원에 대한 인간 단클론 항체 및 이의 용도
CN119751578A (zh) * 2025-03-10 2025-04-04 南昌大学第一附属医院 结直肠癌新抗原免疫多肽及其应用

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
BR9708161A (pt) 1996-03-11 1999-07-27 Epimmune Inc Peptídeos com aumentada afinidade de ligação para moléculas hla
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
AU768834B2 (en) 1998-04-01 2004-01-08 Yale University A method for selectively modulating the interactions between survivin and tubulin
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
JP2003517310A (ja) * 1999-12-10 2003-05-27 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｍａｇｅ２／３に対する細胞性免疫応答の誘導
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20040180354A1 (en) 2002-09-06 2004-09-16 Simard John J.L. Epitope sequences
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
US20050100883A1 (en) 2003-11-12 2005-05-12 Wang Chang Y. Peptide-based diagnostic reagents for SARS
EP2087904B1 (fr) 2003-11-19 2013-08-28 Survac ApS Utilisation thérapeutique de peptides dérivées du Bcl-XL protéine sur des patients atteints du cancer
ES2390967T3 (es) 2004-01-20 2012-11-20 Aichi Prefecture Epítopo/péptido reconocido por LTC específico para Ep-CAM con restricción por ALH-A2402 y su utilización
CA2566506A1 (fr) 2004-06-01 2005-12-15 Innogenetics N.V. Peptides destines a induire une reponse ctl et/ou htl au virus de l'hepatite c
US20080206270A1 (en) 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
EP2657338B1 (fr) 2005-01-25 2015-07-08 NEC Corporation Peptide de liaison HLA, fragment d'ADN et vecteur de recombinaison codant pour ce peptide de liaison HLA
JP2008528643A (ja) * 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
CN100402554C (zh) 2005-02-25 2008-07-16 李玉新 睾丸特异性蛋白50人源抗体的制备及用途
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
GB0520067D0 (en) 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
US7993638B2 (en) 2006-03-01 2011-08-09 Janssen Pharmaceutica Nv Cancer treatment combining lymphodepleting agent with CTLs and cytokines
AU2007298494B2 (en) * 2006-09-21 2013-09-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2665568C (fr) 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation de cellules presentant l'antigene artificielles inactivees et leur utilisation dans des therapies cellulaires
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
EP2155782A2 (fr) 2007-03-26 2010-02-24 Dako Denmark A/S Complexes peptidiques du cmh et leurs utilisations dans des maladies infectieuses
EP2042600A1 (fr) 2007-09-28 2009-04-01 Commissariat A L'energie Atomique Epitope de cellule CD4+ T publique et immunogène de la protéine tat vih et ses applications
AU2009232774B2 (en) 2008-03-31 2014-05-29 Tella Inc. Partial peptide of Survivin presented on MHC class II molecule and use thereof
RS53872B2 (sr) 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
US20120244145A1 (en) 2009-11-16 2012-09-27 Duke University Enhanced immunological responses
US20170039314A1 (en) 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2012051282A2 (fr) 2010-10-14 2012-04-19 The Ohio State University Research Foundation Diagnostic et thérapie du cancer ciblés sur des protéines de type piwil2 (pl2l)
CA2830772C (fr) 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides presentant une affinite pour les proteines de choc thermique (hsp) et complexes associes a une hsp (hacs) et leur utilisation en diagnostic et en therapie
JPWO2012141201A1 (ja) * 2011-04-11 2014-07-28 公立大学法人大阪市立大学 癌免疫療法のためのペプチド及びその利用
CN102973950B (zh) * 2011-09-06 2015-05-27 四川百利药业有限责任公司 Prame、wt1双价肿瘤dna疫苗
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
WO2014127276A1 (fr) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Vaccins contre le cancer ovarien et méthodes de vaccination
EP2978450B1 (fr) 2013-03-27 2018-09-19 ImmunoVaccine Technologies Inc. Méthode d'amélioration de l'efficacité d'un vaccin à base de survivine pour le traitement du cancer
BR112015025460B1 (pt) * 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
WO2014180490A1 (fr) 2013-05-10 2014-11-13 Biontech Ag Prédiction de l'immunogénicité d'épitopes de lymphocytes t
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
WO2015164798A1 (fr) 2014-04-25 2015-10-29 Tria Bioscience Corp. Compositions de support d'haptène synthétique et procédés
EP3193892A4 (fr) 2014-09-14 2018-09-12 Washington University Vaccins anticancéreux personnalisés, et procédés correspondants
US20160074489A1 (en) 2014-09-15 2016-03-17 Regen Biopharma, Inc Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturation
AU2015358387B2 (en) * 2014-12-03 2019-07-25 Verik Bio, Inc. Identification, selection and use of high curative potential T cell epitopes
CN107531736B (zh) 2015-01-06 2022-04-15 免疫疫苗科技公司 脂质a模拟物、其制备方法和用途
RU2719033C2 (ru) 2015-04-23 2020-04-16 Нантомикс, Ллс Способ получения фармацевтического агента для иммунотерапии рака
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
JP6851983B2 (ja) 2015-05-01 2021-03-31 イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法
US11090332B2 (en) 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
BR112017027653A2 (pt) * 2015-06-29 2018-08-28 Ose Immunotherapeutics método para induzir a resposta de memória t precoce com vacina anti-tumoral de peptídeos curtos
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
US9790562B2 (en) 2015-09-30 2017-10-17 Augusta University Research Institute, Inc. Compositions and methods for the detection or treatment of uterine leiomyosarcoma
CA3003251A1 (fr) 2015-10-12 2017-04-20 Nantomics, Llc Systemes, compositions, et procedes de decouverte de msi et de neoepitopes qui prevoient la sensibilite a des points de controle immunitaires
CN105219723A (zh) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活胃癌特异性免疫反应的试剂盒
CA3005127C (fr) 2015-11-18 2023-01-24 Immunovaccine Technologies Inc. Systemes adjuvant et compositions vaccinales sans eau comprenant un adjuvant de type polyi:c et un adjuvant lipidique
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
AU2017264947B2 (en) 2016-05-13 2023-08-31 Medical & Biological Laboratories Co., Ltd. Peptide exchange system and method
JP2020503840A (ja) 2016-10-07 2020-02-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｈｌａ拘束性ｖｇｌｌ１ペプチドおよびその使用
WO2018102585A1 (fr) 2016-11-30 2018-06-07 Advaxis, Inc. Immunothérapie personnalisée en association avec une immunothérapie ciblant des mutations de cancer récurrentes
TWI796314B (zh) * 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
AU2018226566B2 (en) 2017-03-03 2025-01-23 Treos Bio Limited Population-based immunogenic peptide identification platform
EP3370065A1 (fr) 2017-03-03 2018-09-05 Treos Bio Kft Peptides immunogènes
EP3369431A1 (fr) 2017-03-03 2018-09-05 Treos Bio Kft Vaccin
US20200230057A1 (en) 2017-07-10 2020-07-23 Immunovaccine Technologies Inc. Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses Thereof
CN111655714A (zh) 2017-11-08 2020-09-11 阿德瓦希斯公司 来自癌症相关蛋白的免疫原性异变肽及其使用方法
EP3706713A4 (fr) 2017-11-09 2021-06-16 ImmunoVaccine Technologies Inc. Compositions pharmaceutiques, procédés de préparation comprenant le dimensionnement de particules de vésicules lipidiques et leurs utilisations
TWI837109B (zh) 2017-12-28 2024-04-01 美商磨石生物公司 靶向共有抗原之抗原結合蛋白
US20210213066A1 (en) 2018-05-18 2021-07-15 Children's National Medical Center Improved cell therapy compositions for hematopoietic stem cell transplant patients
JP2021526365A (ja) 2018-05-18 2021-10-07 チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 改善された標的化ｔ細胞療法
GB201814361D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
CA3119910A1 (fr) 2018-11-19 2020-05-28 Immunovaccine Technologies Inc. Methodes d'amelioration de l'efficacite d'un agent therapeutique a base de survivine dans le traitement de tumeurs
US20220064598A1 (en) 2019-01-07 2022-03-03 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
EP3908292A4 (fr) 2019-01-07 2023-01-04 Children's National Medical Center Thérapie améliorée à lymphocytes t ciblés pour le traitement du myélome multiple
EP4045011A1 (fr) 2019-10-16 2022-08-24 ImmunoVaccine Technologies Inc. Formulations d'émulsion à phase continue aqueuse pour l'administration d'agents actifs ou thérapeutiques
CN110713546B (zh) 2019-10-31 2021-04-20 中国医科大学附属第一医院 靶向survivin-XIAP复合物的抗肿瘤多肽Sur-X与用途
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine

Also Published As

Publication number Publication date
EP3846845A1 (fr) 2021-07-14
JP2021536487A (ja) 2021-12-27
JP7642530B2 (ja) 2025-03-10
CO2021004019A2 (es) 2021-07-19
JP2024097033A (ja) 2024-07-17
CN113329761A (zh) 2021-08-31
SA521421371B1 (ar) 2024-06-06
IL281224A (en) 2021-04-29
US20230102031A1 (en) 2023-03-30
US20240000911A1 (en) 2024-01-04
US11666644B2 (en) 2023-06-06
SG11202101888YA (en) 2021-03-30
CL2024001738A1 (es) 2024-11-15
MX2021002449A (es) 2021-08-05
WO2020048990A1 (fr) 2020-03-12
BR112021004071A2 (pt) 2021-06-01
CA3110760A1 (fr) 2020-03-12
CL2021000532A1 (es) 2021-09-24
KR20210086612A (ko) 2021-07-08
AU2019334437A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
MA47677A (fr) Vaccins peptidiques
IL284348A (en) Hiv pre-immunization and immunotherapy
PL3727460T3 (pl) Bicykliczne ligandy peptydowe swoiste wobec epha2
IL263846B (en) Formulation of a peptide vaccine
DK3609535T3 (da) Hbv-vaccine
DK3723783T3 (da) Mitokondrie-målrettede peptider
DK3393505T3 (da) Rekombinante zika-vacciner
EP3700565A4 (fr) Vaccins avec adjuvant
EP3773649A4 (fr) Vaccins anticancéreux personnalisés
HUE053347T2 (hu) Glikopeptid-készítmények
EP3603619A4 (fr) Formulation d'adjuvant vaccinal
IL281224A (en) Peptide compounds
MA52011A (fr) Vaccins peptidiques contre l'interleukine-31
HUE055762T2 (hu) Nyújtott hatású készítmények
MA52180A (fr) Vaccins thérapeutiques anti-abêta
EP3560512A4 (fr) Composition de vaccin contre le zona
EP3743084A4 (fr) Vaccins antiviraux recombinants
DK3826600T3 (da) Isforet vaccinekøleskab
LT3522905T (lt) Imunogeniniai arginazės peptidai
PL3709970T3 (pl) Preparaty linezolidu
EP3638297A4 (fr) Vaccin bactérien
EP3765067C0 (fr) Vaccins autologues contre le cancer
DK3274447T3 (da) Rekombinant fåresygevirus jeryl lynn 2 baseret vaccine
EP3528843A4 (fr) Vaccins anti-opioïdes
EP3518957C0 (fr) Protéine thérapeutique